Macro Group Pharmaceuticals - Macro Capital S.A.E results, Q1 2024
Net profit, assets, equity and cash flow for Q1 2024, against the same period a year earlier, from the published financial statements.
Net profit-27.91 millionEGP · −395.5% vs the same period a year earlier
Total assets439 millionEGP · −44.9% vs the same period a year earlier
Shareholders' equity38.04 millionEGP · −89.9% vs the same period a year earlier
Operating cash flow-23.5 millionEGP · +77.6% vs the same period a year earlier
In short
- Macro Group Pharmaceuticals - Macro Capital S.A.E's net profit for Q1 2024 was about -27.91 million EGP, down −395.5% from 9.44 million EGP in Q1 2023.
- Total assets at the end of Q1 2024 were about 439 million EGP, and shareholders' equity about 38.04 million EGP.
- Operating cash flow for Q1 2024 was negative at 23.5 million EGP.
Key lines against the same period a year earlier
This periodQ1 2023Change
Net profit-27.91 million9.44 million−395.5%
Gross profit40.17 million118 million−66.1%
Total assets439 million798 million−44.9%
Total liabilities394 million421 million−6.4%
Shareholders' equity38.04 million376 million−89.9%
Total liabilities and equity432 million798 million−45.8%
Operating cash flow-23.5 million-105 million+77.6%
Investing cash flow-253 thousand-1.59 million+84.1%
Financing cash flow45.12 million-51.65 million+187.4%
Net change in cash21.36 million-158 million+113.5%
Figures in EGP from the published statement summaries (consolidated where the company publishes consolidated statements), after normalising reporting units across periods. The exact figure is in the attached report, which may be the standalone version. Figures are as shown in the published statement summary; quarterly figures may be cumulative from the start of the fiscal year.
Macro Group Pharmaceuticals - Macro Capital S.A.E's Q3 2026 results, the day they are published
One email on the day, no account, and a one-click stop in the email itself.
By subscribing you agree to receive these alerts only. Privacy policy